Sormani MP and Bruzzi P. MRI lesions as a surrogate
for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013; 12 (7) : 669-676. 9 This lack of long-term effect is the rationale behind not treating non-disabling clinical attacks with corticosteroids, as the potential benefits do not seem to outweigh the potential risks. Therefore, treating an asymptomatic new lesion with corticosteroids is not justified if we do not currently use them to treat all clinical attacks.
Fourth, when considering disease-modifying treatment (DMT) initiation or switch: MRI is a very sensitive tool for monitoring inflammatory activity as new lesions occur more frequently than clinical attacks. 2, 10 As such, presence and number of new lesions are widely used together with relapses and/or Expanded Disability Status Scale (EDSS) increase in scores developed to evaluate treatment response. 11 In general, the treatment effect on lesion accrual predicts the effect on relapses both in clinical trials and at the group level. 10, 11 This, however, may not be so straightforward at the individual level as Declan et al. point out. Relapses may be better than MRI to assess disease activity in patients with pre-existing or new comorbidities that also affect the white matter. In addition, a small lesion number is not associated with long-term disability 5 but, as mentioned before, the topography of the new lesion could be more relevant. 6 Conversely, MRI may provide more objective evidence than clinical assessment since, for instance, clinical attacks without new lesions on the MRI may in fact be pseudorelapses. However, it is also possible that not all new lesions will be detected with conventional MRI, like lesions located in the grey matter. 12 In summary, in such a complex disease as MS, to this date, clinical and MRI information complement each other and should be assessed together to inform the treatment decision-making process in MS, tailored to the individual level.
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